Outcome of EGFR mutant patirnts included in a clinical trial after progression on EGFR TKI
Pardo Aranda, Nuria, Remon, Jordi, Martinez Marti, Alex, Martinez de Castro, Ana Maria, Cedres Perez, Susana, Navarro, Alejandro, Scheenaard, Eulalia, Piera, Adelaida, Carbonell, LLuisa, Vivancos, Ana, Felip, Enriqueta, Gámez Córdoba, Esther
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Outcome of KRAS mutated (m) non-small cell lung cancer (NSCLC) patients (pts) treated with immune checkpoint inhibitors (immuneCI)
Pardo Aranda, Nuria, Viaplana, Cristina, Remon, Jordi, Martinez Marti, Alex, Cedres Perez, Susana, Navarro, Alejandro, Martinez de Castro, Ana Maria, Villacampa, Guillermo, Carbonell, LLuisa, Hernando, Alberto, Vivancos, Ana, Dienstmann, Rodrigo, Felip, Enriqueta
Published in Journal of clinical oncology (20.05.2017)
Published in Journal of clinical oncology (20.05.2017)
Get full text
Journal Article
Results of patients with thoracic cancers older than 70 years included in clinical trials: A center experience
Martinez Marti, Alex, Cabrera, Guadalupe, Ortiz, Carolina, Vilaro, Marta, Miquel, Josep M, Cedres Perez, Susana, Navarro, Alejandro, Pardo Aranda, Nuria, Martinez, Pablo, Piera, Adelaida, Carbonell, LLuisa, De la Fuente, Iris, Garcia, Silvia, Sansano, Irene, Felip, Enriqueta
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
Analysis of clinical characteristics and outcomes of ALK positive (ALK+) patients treated with ALK inhibitors (ALKi)
Cedres Perez, Susana, Pardo Aranda, Nuria, Navarro, Alejandro, Martinez Marti, Alex, Martinez de Castro, Ana Maria, Cabrera, Guadalupe, Vilaro, Marta, Carbonell, LLuisa, de la Fuente, Iris, Piera, Adelaida, Martinez, Lidia, Hernandez-Losa, Javier, Sansano, Irene, Felip, Enriqueta
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC)
De Castro, Am Martinez, Navarro, Alejandro, Perez, Susana Cedres, Martinez, Alex, Pardo, Nuria, Hernando, Alberto, Ortiz, Carolina, Amair, Fabiola, Biosca, M., Aguilar-Company, Juan, Scheenaard, Eulalia, Recasens, Sergi, Carbonell, Lluisa, Retter, Andrea, Martinez, Sonia, Piera, Adelaida, Valverde, Sonia, Velez, Lidia, Matas, Silvia García, Vilaro, Marta, Felip, Enriqueta
Published in Journal of thoracic oncology (01.01.2017)
Published in Journal of thoracic oncology (01.01.2017)
Get full text
Journal Article
P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint-Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC): Topic: IT Biomarkers
De Castro, Am Martinez, Navarro, Alejandro, Perez, Susana Cedres, Martinez, Alex, Pardo, Nuria, Hernando, Alberto, Ortiz, Carolina, Amair, Fabiola, Biosca, M., Aguilar-Company, Juan, Scheenaard, Eulalia, Recasens, Sergi, Carbonell, Lluisa, Retter, Andrea, Martinez, Sonia, Piera, Adelaida, Valverde, Sonia, Velez, Lidia, Matas, Silvia García, Vilaro, Marta, Felip, Enriqueta
Published in Journal of thoracic oncology (01.01.2017)
Published in Journal of thoracic oncology (01.01.2017)
Get full text
Journal Article